BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/13/2025 6:51:09 AM | Browse: 155 | Download: 333
 |
Received |
|
2025-06-16 10:16 |
|
Peer-Review Started |
|
2025-06-16 10:16 |
|
First Decision by Editorial Office Director |
|
2025-07-10 09:12 |
|
Return for Revision |
|
2025-07-10 09:12 |
|
Revised |
|
2025-07-22 12:28 |
|
Publication Fee Transferred |
|
2025-07-23 11:34 |
|
Second Decision by Editor |
|
2025-10-09 01:11 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-10-09 02:50 |
|
Articles in Press |
|
2025-10-09 02:50 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-10-30 09:45 |
|
Publish the Manuscript Online |
|
2025-11-13 06:51 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Precision therapy guided by genotypic antibiotic resistance for Helicobacter pylori eradication: A prospective, randomized controlled trial
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yan Xu, Jing-Wen Hao, Cong-Cong Min, Lin Yang, Cui-Ping Ma, Chao Shi, Tao Mao, Zi-Bin Tian, Tong Wang and Ya-Nan Yu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Qilu Health Outstanding Young Talent Cultivation Project |
QDFY-3839 |
|
| Corresponding Author |
Ya-Nan Yu, MD, Professor, Department of Gastroenterology, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao 266000, Shandong Province, China. yananyu@qdu.edu.cn |
| Key Words |
Helicobacter pylori; Antibiotic resistance; Precision medicine; Eradication rate; First-line therapy |
| Core Tip |
Antibiotic resistance in Helicobacter pylori (H. pylori) has reduced the efficacy of traditional eradication regimens. This randomized controlled trial in northern China used rapid genotypic antibiotic susceptibility testing (G-AST) to guide first-line therapy by tailoring regimens according to detected resistance mutations, including tetracycline for dual-resistant strains. G-AST-guided therapy significantly improved eradication rates compared with standard bismuth quadruple therapy without increasing adverse events. These findings demonstrate the feasibility and clinical benefit of molecular-guided personalized treatment, offering a promising strategy to overcome antibiotic resistance in H. pylori infection. |
| Publish Date |
2025-11-13 06:51 |
| Citation |
Xu Y, Hao JW, Min CC, Yang L, Ma CP, Shi C, Mao T, Tian ZB, Wang T, Yu YN. Precision therapy guided by genotypic antibiotic resistance for Helicobacter pylori eradication: A prospective, randomized controlled trial. World J Gastroenterol 2025; 31(42): 110717 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i42/110717.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i42.110717 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
